This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Brisco, M. J. Articles by Morley, A. A. Search for Related Content PubMed PubMed Citation Articles by Brisco, M. J. Articles by Morley, A. A.

Early Resistance to Therapy during Induction in Childhood Acute Lymphoblastic Leukemia¹

Department of Hematology and Genetic Pathology, Flinders University of South Australia and Flinders Medical Center, South Australia 5042 [M. J. B., P. J. S., G. D., E. H., S-H. N., L. E. S., A. A. M.]; Department of Laboratory Medicine, West China University of Medical Sciences, Chengdu 610041, People’s Republic of China [L. P.]; and Department of Hematology/Oncology, Women’s and Children’s Hospital, North Adelaide, South Australia 5006 [I. R. G. T., M. S. R.]

Many patients with acute lymphoblastic leukemia (ALL) are not cured by current therapy because of the development of drug resistance. It is not clear when resistance develops during the growth of the leukemic clone and whether resistant cells are already present at diagnosis or develop later during treatment. Twenty-two uniformly treated children with ALL were studied throughout induction treatment. The size of the leukemic clone in blood and marrow was estimated by limiting dilution PCR analysis, using the rearranged immunoglobulin heavy chain gene as a molecular marker. The decline in the number of leukemic cells was biphasic in virtually all patients. For both marrow and blood, the logarithmic mean of the number of leukemic cells fell by approximately four orders of magnitude during the first 2 weeks, one order of magnitude during the third week, and not at all during the last two weeks of induction treatment. For marrow, the median of the fraction of leukemic cells in each patient that survived per week of treatment was 0.008 for the first 2 weeks, 0.12 for the third week, and 1.4 for the last 2 weeks; for blood, the corresponding figures were 0.003, 0.14, and 0.69, respectively. In individual patients, the results for marrow and blood showed good correlation. The biphasic decline of leukemic cell number suggests that most leukemic cells were sensitive to treatment and were rapidly killed, leaving behind a minor but substantial population of drug-resistant cells. The most likely explanation for this phenomenon is that these resistant cells were already present at diagnosis, their resistance having originated from genetic or epigenetic mutations during prior growth of the leukemic clone.

This article has been cited by other articles:

				D. Bhojwani, H. Kang, R. X. Menezes, W. Yang, H. Sather, N. P. Moskowitz, D.-J. Min, J. W. Potter, R. Harvey, S. P. Hunger, et al. Gene Expression Signatures Predictive of Early Response and Outcome in High-Risk Childhood Acute Lymphoblastic Leukemia: A Children's Oncology Group Study J. Clin. Oncol., September 20, 2008; 26(27): 4376 - 4384. [Abstract] [Full Text] [PDF]

				C. Flotho, E. Coustan-Smith, D. Pei, C. Cheng, G. Song, C.-H. Pui, J. R. Downing, and D. Campana A set of genes that regulate cell proliferation predicts treatment outcome in childhood acute lymphoblastic leukemia Blood, August 15, 2007; 110(4): 1271 - 1277. [Abstract] [Full Text] [PDF]